Tempus AI raises FY2026 outlook as diagnostics and data grow

Transcript intelligence

What changed

Management raised FY2026 revenue guidance to $1.59–$1.60 billion and set a $65 million adjusted EBITDA target. The call also highlighted new Merck and expanded Gilead collaborations and a data portfolio exceeding 500 petabytes; the prior-quarter analysis described guidance as maintained and data holdings above 450 petabytes.

Guidance delta

Raised FY2026 revenue guidance to $1.59–$1.60 billion; adjusted EBITDA target is $65 million.

Key takeaways

• Revenue grew 36% year over year; oncology diagnostics rose 35% and data applications rose 40.5%.
• New Merck and expanded Gilead collaborations add multi-year data-revenue opportunities, though deal scope and delivery visibility remain open questions.
• Management cited pending FDA submissions and amendments for XF and XT among the key regulatory priorities.
• MRD and hereditary testing growth remains linked to reimbursement conditions.

Management priorities

• Expand data licensing and modeling to additional pharma partners.
• Advance FDA processes for XF, XT tumor-only, and XR assays.
• Accelerate MRD rollout as reimbursement improves.
• Develop multimodal models in Alzheimer’s and explore other rare-disease applications.
• Continue AI platform development using GPU infrastructure.